Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to d

Experienced Industry Leader Brings Two Decades of Finance, Strategic and Operational Expertise Exper

All Evaluable Patients Achieved Improvements in Multiple Hallmarks of MYBPC3-Associated HCMBenefits

Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to di

Tenaya reported early RIDGE-1 data showing reduced arrhythmias and favorable safety for TN-401 in PK

Tenaya Therapeutics (NASDAQ:TNYA) reported quarterly losses of $(0.09) per share which missed the an

Readout to Include One-Year Cohort 1 Results and Early Cohort 2 Data; Webcast Conference Call Planne

Tenaya Therapeutics (NASDAQ:TNYA) reported quarterly losses of $(0.12) per share which beat the anal

Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to d

Tenaya Therapeutics stock jumps after announcing a research collaboration with Alnylam worth up to $

Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to di

Aims to Build on Positive 2025 Interim TN-201 Results in First Half of 2026 with Longer-Term Follow-

Heart disease-focused Tenaya Therapeutics falls on high volume after pricing a $60 million offering

HC Wainwright & Co. analyst Joseph Pantginis maintains Tenaya Therapeutics (NASDAQ:TNYA) with

Chardan Capital analyst Geulah Livshits maintains Tenaya Therapeutics (NASDAQ:TNYA) with a Buy an

Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to di

TN-401 was Well Tolerated at 3E13 vg/kg dose Robust Transduction and Demonstrated Increases in PKP2

Chardan Capital analyst Geulah Livshits maintains Tenaya Therapeutics (NASDAQ:TNYA) with a Buy an

Tenaya Therapeutics (NASDAQ:TNYA) reported quarterly losses of $(0.12) per share which beat the anal

MyPEAK-1 Data Presented During Late-Breaking Session at AHA Scientific Sessions 2025 with Simultaneo

The U.S. Food and Drug Administration ("FDA") has placed a clinical hold on MyPEAKTM-1,Tenay

Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to di

Several biotech stocks are showing renewed strength over the past week, with their Momentum scores s

HC Wainwright & Co. analyst Joseph Pantginis reiterates Tenaya Therapeutics (NASDAQ:TNYA) wit

Largest Noninterventional Natural History Study of People Under 18 with MYBPC3-associated HCM with M

HC Wainwright & Co. analyst Joseph Pantginis reiterates Tenaya Therapeutics (NASDAQ:TNYA) wit

U.S. stocks were lower, with the Dow Jones index falling around 100 points on Friday. Shares of Bl

Shares of Fluor Corporation (NYSE: FLR) fell during Tuesday’s session following fourth-quarter resu

Gainers Trevena, Inc. (NASDAQ: TRVN) shares surged 170% to $1.74 after the company announced the

Gainers Mangoceuticals, Inc. (NASDAQ: MGRX) shares jumped 207% to $2.84. The company announced Th

Gainers Aditxt, Inc. (NASDAQ: ADTX) shares gained 68.6% to $1.45. Aditxt signed asset purchase ag

Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares surged 56.6% to settle at $19.10 on Friday.

  On Wednesday, 283 companies set new 52-week lows.

  Friday's session saw 236 companies set new 52-week lows.

  During Monday's session, 101 companies made new 52-week lows.

  On Tuesday, 838 companies hit new 52-week lows.

  During Monday's trading, 528 companies set new 52-week lows.

  During Monday's session, 402 companies made new 52-week lows.

  On Thursday, 1076 companies hit new 52-week lows.

  On Monday, 429 stocks made new 52-week lows.